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Soon after the broad-spectrum, highly
effective antibiotics fluoroquinolones were intro-
duced, their extensive use and misuse in
hospitals and communities, as well as in
veterinary medicine, have led to the emergence
and spread of resistant strains (1,2). Highly
divergent rates of fluoroquinolone resistance in
both community-acquired and nosocomial patho-
gens have been reported worldwide (2). Many
factors, including patient characteristics, local
epidemiologic factors, antibiotic policies, over-
the-counter use (which often leads to inadequate
use), lower standard of living in developing
countries, lack of information on the prudent use
of antibiotics, and use of antibiotics in animal
husbandry may contribute to the emergence of
quinolone-resistant organisms.
Surveillance is an integral part of controlling
resistance, and local and national surveys to
identify, monitor, and study the epidemiology of
the emergence and spread of resistant isolates
are needed (3). To identify national trends and
local differences in the epidemiology of quinolone
resistance in Greece, we report 1997 ciprofloxacin
susceptibility data from the National Electronic
System for the Surveillance of Antimicrobial
Resistance.
The National Electronic System for the
Surveillance of Antimicrobial Resistance was
introduced in Greece 3 years ago. Involving 17
hospitals throughout Greece, the system
analyzes the routine results of the antibiotic
sensitivity tests performed in hospital microbiol-
ogy laboratories by using WHONET software (4).
In our analysis we included 11,097 isolates
(4,204 from medical wards, 2,897 from surgical
wards, 1,724 from intensive care units [ICU],
and 2,272 from outpatient departments) (Table 1).
We focused on the bacteria most frequently
encountered in Greek hospitals (National
Electronic System for the Surveillance of
Antimicrobial Resistance [www.mednet.gr/
whonet]; N.J. Legakis, Enare Sentry, unpub.
data): Escherichia coli, Klebsiella pneumoniae,
Enterobacter species, Pseudomonas aeruginosa,
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Table 1. Isolates included in the analysisa
Type of ward
Medi- Surgi- Outpa-
Species cal cal ICUb tients All
Escherichia 2,100 1,114      94 1,571   4,879
  coli
Pseudomonas    672    527    570    195   1,964
  aeruginosa
Staphylococcus    452    467    318    248   1,485
  aureus
Enterobacter    396    332    198    142   1,068
  spp.
Klebsiella    419    224    177      96      916
  pneumoniae
Acinetobacter    165    233    367      20      785
  spp.
All 4,204 2,897 1,724 2,272 11,097
aOne isolate per species per patient (the first isolated) is
shown.  bICU, intensive care unit.472 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table 2. Ciprofloxacin resistance by specimen and type of warda
Outpatients Medical Surgical ICU
No. %Rb No. %R No. %R No. %R
Escherichia coli
  Urine 1,191   5.0               1,572   5.5  597     8.5   39 10.2
  Blood      -   195   6.9    14   18.1     5   0.0
  Respiratory      -     56   2.1      -   23   9.0
  Pus      -     33 12.1  203     8.4   11 27.8
  Other    380   4.5   244   7.5  300     6.5   16 20.0
  All 1,571   3.7               2,100   5.6              1,114     8.2   94 13.3
Salmonella spp.
  Stool    195   0.7
Klebsiella pneumoniae
  Urine      62   6.6   254 15.5   85   19.8   28 64.0
  Blood      -     45 11.3   10     9.8   18 72.3
  Respiratory      -     62   9.8   12   50.0   90 69.8
  Pus      -     14 50.0   42   19.0     0   0.0
  Other      34   3.1     44 18.5   79   28.3   41 65.4
  All     96   5.4   419 15.8 226   23.9 177 67.7
Serratia marcences
  All     76c   7.7c   20 45.2
Enterobacter spp.
  Urine      76 12.0   190 29.7   85   32.0   24 75.4
  Blood      -     37 21.8   13   54.2   24 66.6
  Respiratory      -     76   6.3   10   40.2   58 48.6
  Pus      -     22 36.8 138   18.5   27 67.6
  Other      66 10.8     71 16.9   86   23.3   65 69.0
  All    142 11.6   396 22.2 332   24.8 198 62.2
Pseudomonas aeruginosa
  Urine      51 31.0   270 44.0 171   40.7   70 79.3
  Blood       0   0.0     24 20.6   13   46.5   29 75.6
  Respiratory      11 18.2   258 34.4   29   44.6 379 62.9
  Pus      18 11.3     35 31.6 147   22.6   16 69.5
  Ear      72   1.7       7 47.3   30     3.7     0   0.0
  Other      43 18.8     78 26.9 137   25.9   76 66.9
  All    195 16.7   672 37.5 527   28.2 570 66.4
Acinetobacter spp.
  Urine      -     72 62.6   32   65.9   34 94.4
  Blood      -     18 38.7   16   69.0   40 92.3
  Respiratory      -     38 49.7   11 100.0 190 91.0
  Pus      -     13 61.8   87   60.1   19 94.8
  Other      -     24 62.5   87   69.1   84 78.9
  All     20 45.1   165 56.8 233   66.6 367 88.4
Staphylococcus aureus
  Urine     -     37 32.9   16   31.0    -
  Blood     -   101 51.0   15   67.0   40 62.7
  Respiratory     -   123 45.3   28   57.1 221 65.8
  Pus   104 18.2     88 21.6 272   30.8   14 71.4
  Ear     52   3.8      -   -   -
  Other     92 10.3   103 25.6 136   31.4   43 67.4
  All   248 12.8   452 30.5 467   33.0 318 63.6
  MRSAd     40 56.7   140 69.1 176   75.3 375 94.3
  MSSAe   184   1.7   256 12.4 219     6.5   92   4.6
aOne isolate per patient (the first isolated) is shown. bR, resistant. cMedical and surgical wards combined. dMRSA, methicillin-
resistant S. aureus. eMSSA, methicillin-sensitive S. aureus.
Acinetobacter baumanii, and Staphylococcus
aureus. These species are also the most
important nosocomial pathogens in most parts of
the world in terms of rate of isolation,
pathogenicity, and virulence (5,6).
Isolation and identification were performed
by standard methods at the microbiology
laboratories of each hospital participating in the
network. The susceptibility testing methods
were Kirby-Bauer disk diffusion (7 hospitals);
Sensititre (Sensititre, Salem, NH) (1); Pasco
(Difco, Detroit, MI) (8); and VITEK (Bieux-
Merieux Marcy lEtoile, France) (1). The actual
zone diameters or MICs (not the interpretations
of the tests) were entered into WHONET. The
chi-square test was used to evaluate differences
in resistance rates between types of wards, as
well as between clinical specimens. Pearsons
correlation coefficients were calculated for
possible associations between resistance rates
and hospital size.
The resistance rate to ciprofloxacin by type of
ward, clinical specimen, and bacterial species is
shown in Table 2. There is a stepwise decrease in
the frequency of isolation of ciprofloxacin-
resistant isolates (ciprofloxacin resistance in473 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Table 3. Resistant phenotypes of ciprofloxacin-resistant isolates to other classes of antibioticsa
Klebsiella pneumoniae Enterobacter spp Escherichia coli
Phenotypeb No.     % Phenotype No.      % Phenotype No.   %
F     4     3.7 F     0        0 F   25 15.1
DBXF     9     8.4 IF     4     2.5 IDBXF   16   9.6
IDB F   16   15.0 IDB F     7     4.4 IXF   29 17.5
IDBXF   64   59.8 IDBXF 131   82.9 XF   42 25.3
all other   14   13.1 all other   16   10.1 all other   54 32.5
All 107 100.0 All 158 100.0 All 166     100.0
Pseudomonas aeruginosa Acinetobacter baumanii
Phenotype  No.       % Phenotype No.      %
F   10     7.3 F     0     0.0
1DM F   14   10.2 SMD XF     5   10.0
1DMNF   23   16.8 D XF   15   30.0
1 M F   40   29.2 MD XF   23   46.0
all other   50   36.5 all other     7   14.0
All                         137          100.0 All   50          100.0
Staphylococcus aureus
MRSA MSSA
Phenotype  No.     % Phenotype No.      %
F     0     0.0 F     7   10.3
OG E F   23   11.3 E F     9   13.2
OG ECF   44   21.7 CF   33   48.5
OGXECF   84   41.4
all other   52   25.6 all other   19   27.9
All 203 100.0 All   68          100.0
aAll wards, intensive care units isolates are not included. b1, piperacillin; B, tobramycin; C, chloramphenicol; D, ceftazidime; E,
erythromycin; F, ciprofloxacin; G, gentamicin; I, cefoxitin; M, amikacin; N, imipenem; O, oxacillin;  S, amoxicillin/sulbactam; X,
cotrimoxazole; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus.
isolates from ICU patients > isolates from surgical
patients > isolates from medical patients > isolates
from outpatients). These differences were signifi-
cant (p <0.01), with the exception of decreases in
resistance rates for E. coli between surgical wards
and ICUs; for Enterobacter spp. between medical
and surgical wards; for Acinetobacter spp.
between outpatients, medical, and surgical
wards; and for S. aureus between medical and
surgical wards. Moreover, for P. aeruginosa, the
resistance rates were significantly higher in
medical than in surgical wards (p = 0.00097).
As for clinical specimens, each bacterial
species followed a different pattern (Table 2). In
medical wards, enterobacterial strains isolated
from purulent infections were more often
resistant to ciprofloxacin, but this difference was
statistically significant only for K. pneumoniae
(p = 0.012). In surgical wards, blood and
respiratory isolates were more often resistant,
but this difference was significant only for
Enterobacter  spp. (p = 0.02). On the other hand,
ciprofloxacin-resistant  P. aeruginosa strains
were more frequently isolated (p = 0.0021) in
medical wards from urine and in surgical wards
from urine and blood as opposed to all other
specimens (p = 0.0005). No significant differ-
ences were observed in the rate of isolation of
ciprofloxacin-resistant A. baumanii strains among
the various clinical specimens. S. aureus strains
resistant to ciprofloxacin were mostly methicil-
lin-resistant (MRSA) (Table 2). Very low resistance
rates were observed in P. aeruginosa isolated
from ear infections, especially from outpatients.
Approximately 75% of K. pneumoniae, 87% of
Enterobacter  spp., 55% of P. aeruginosa, 76%
of A. baumanii, and 75% of MRSA strains were
drug resistant to at least three different classes
(Table 3). However, 15% of the ciprofloxacin-
resistant E. coli were resistant only to this
antibiotic, and 25% had additional resistance
only to cotrimoxazole. Moreover, 48% of
ciprofloxacin-resistant but methicillin-sensitive
S. aureus were resistant only to chloramphenicol.
When we plotted resistance rates to
ciprofloxacin against the number of beds in each
hospital, we found no correlation (Figure). The
rate of isolation of ciprofloxacin-resistant isolates
varied greatly by hospital for all species examined:
from 1% to 15% for E. coli, 1% to 23% for
K. pneumoniae, 1% to 33% for Enterobacter spp.,
11% to 33% for P. aeruginosa, 29% to 73% for474 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Figure. Resistance rates to ciprofloxavin in each hospital by number of beds and geographic area of the hospital.
Only hospitals with more than 20 isolates are included. (Isolates from all wards but not intensive care units.)475 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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A. baumanii, and 11% to 48% for S. aureus.
Ciprofloxacin resistance was observed in
hospitals throughout Greece.
In Europe and North America, a striking
difference in the incidence of bacterial resistance
to quinolones has been observed between
nosocomial and community-acquired infections;
resistance is only rarely encountered among the
latter (2,7). The incidence of resistance to
fluoroquinolones in bacteria isolated from
hospital-acquired infections varies among bacte-
rial species, clinical settings, and countries and
may be related to local epidemic spread of a few
clones (2). The highest incidence of resistance is
among  P. aeruginosa, Acinetobacter spp.,
Serratia marcescens, and particularly MRSA
strains (8). Our results place Greece among the
countries with high resistance levels to
quinolones. Although quinolones are among the
antibiotics restricted by the Greek Ministry of
Health and Welfare, the mean national level of
quinolone resistance has increased in most
bacterial species during the last 5 years (9).
The 3.7% quinolone resistance rate among
E. coli isolated from outpatients is almost double
that in other industrialized countries (2). This
high rate may be due to the use of quinolones,
and especially norfloxacin, as a first-line
antibiotic in Greece to treat uncomplicated
urinary tract infections in the outpatient setting.
Free access to fluoroquinolones has also been
incriminated in increased quinolone resistance
in industrialized and developing countries
(10,11). The low rate of quinolone resistance in
salmonellas, compared with other countries
(12,13), may be due to infrequent use of
quinolones in farm animals in Greece. Among
Enterobacteriaceae, quinolone resistance seems
to be higher in K. pneumoniae and Enterobacter
spp. than in S. marcescens.
The high level of resistance in ICUs was
expected since ICUs are well-known focuses of
antimicrobial resistance (14). Hospitalization in
ICUs was an independent risk factor for
acquiring infection by multidrug-resistant strains
in Greece (15). Moreover, ICU patients are often
colonized with endemic, multidrug-resistant
strains, which often spread to other wards (16).
We found higher rates of isolation of
quinolone-resistant strains of some species in the
surgical wards than in medical wards. Patients
at high risk for a resistant nosocomial infection
(e.g., cancer patients, immunosupressed pa-
tients) are usually in medical wards. High
resistance in the surgical wards could be the
result of nursing practices or unnecessary
prophylactic administration of antibiotics, both
of which should be further evaluated.
Most quinolone-resistant strains in Greece
are also resistant to other clinically relevant
antibiotics. The possible clinical and epidemio-
logic importance of the newly described
multidrug efflux pumps in multidrug resistance,
mainly in P. aeruginosa, is under investigation
worldwide (17). Moreover, the marginal suscep-
tibility of S. aureus to quinolones and the ease
with which mutations affecting susceptibility
can occur in this species contribute to the
observed high rates of quinolone resistance.
MRSA strains are no more likely to develop
resistance to quinolones than other staphylo-
cocci (8). In any case, the favorable accumulation
of different traits in quinolone-resistant strains
or, alternatively, the favorable potential for
mutation to quinolone resistance in multidrug-
resistant strains has not been proved. Epidemio-
logic parameters, and more specifically the
sequential introduction of various antibiotic
classes in most of the world and in Greek
hospitals, could explain multidrug resistance.
The extensive aminoglycoside and beta-lactamase
use in the 1980s is responsible for the high
prevalence of multidrug-resistant plasmids and
transposons found in the nosocomial strains of
various bacterial genera in Greek hospitals (18-
20). The strains harboring these plasmids can
survive in the hospital environment and become
the best candidates for selection of resistant
mutants under the pressure of quinolones.
That quinolone-resistant strains are found in
hospitals in all parts of Greece and resistance is
not associated with the size of the hospital or its
geographic area are consistent with the high
prescription rate for quinolones. However, the
isolation rate of resistant strains varied
considerably by hospital, perhaps because of
local epidemiologic factors (e.g., prescribing or
nursing habits) or possible (epidemic) spread of
strains among patients.
This study has limitations. First, it is based
on routine data generated in the microbiology
laboratories of participating hospitals. Some-
times different antibiotics are tested in each
hospital, which limits the possibility for
interhospital comparisons. Moreover, different
methods for susceptibility testing are used in476 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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each hospital. Data such as antibiotic consump-
tion or days of hospitalization are not available
since they are not included as information in the
WHONET software and they are difficult and
time-consuming to collect routinely.
Quinolone use is a well-proven independent
risk factor for resistance (21,22). Nevertheless,
local differences indicate that other epidemio-
logic parameters should be further evaluated.
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